Abstract:An SFC‐MS method was developed for the determination of seven vitamin D3 impurities in oily drug products. Optimal SFC and MS conditions were achieved guided by the screening design of experiments, and a rapid saponification and liquid–liquid extraction sample preparation method enabled efficient cleaning and impurity recovery in the complex matrix. Method validation highlighted the method's quantitative performance, underscoring the potential of SFC‐MS in pharmaceutical quality control. Vitamin D3, an essential micronutrient, often requires supplementation via medicines or food supplements, which necessitate quality control (QC). This study presents the development of a method for detecting and quantifying seven impurities of vitamin D3 in oily drug products using supercritical fluid chromatography–mass spectrometry (SFC‐MS). Targeted impurities include two esters of vitamin D3 and five non‐esters including four that are isobaric to vitamin D3. Firstly, a screening study highlighted the Torus 1‐AA column and acetonitrile modifier as adequate for the separation, followed by optimization of the SFC conditions. Secondly, make‐up solvent composition and MS settings were optimized to reach high sensitivity. For both the separation and MS response, the screening design of experiments proved useful. Lastly, a fast saponification and liquid–liquid extraction method was developed, enabling efficient sample cleanup and impurities recovery from the complex oily matrix. The SFC‐MS method suitability was assessed in two validation studies. The first study employed the ICH Q2 guideline for impurity limit test to demonstrate method specificity and establish a limit of detection (LOD) and a limit of quantification (LOQ) at 0.2% and 0.5%, respectively, for ester impurities. The second study conducted a comprehensive quantitative assessment for three non‐ester impurities using a total error approach, determining method validity through accuracy profiles. The validated method exhibited reliable performance across impurity concentrations from 0.1% to 2.0%, with estimated LODs ranging from 2 to 7 ng/mL. This study further promotes SFC‐MS as a valuable, versatile, and green tool for routine pharmaceutical QC.

Identification and Determination of Impurities in a New Therapeutic Agent for Fatty Liver Disease

Assessment of the Purity of IMM-H014 and Its Related Substances for the Treatment of Metabolic-Associated Fatty Liver Disease Using Quantitative Nuclear Magnetic Resonance Spectroscopy

Determination of Methyl Methanesulfonate and Ethyl Methylsulfonate in New Drug for the Treatment of Fatty Liver Using Derivatization Followed by High-Performance Liquid Chromatography with Ultraviolet Detection

Development and In Vitro–In Vivo Correlation Evaluation of IMM-H014 Extended-Release Tablets for the Treatment of Fatty Liver Disease

Simultaneous Quantification of 2′,3′,5′-Tri-o-acetyl-n6-(3-hydroxylaniline)adenosine and Its Principal Metabolites in Hamster Blood by LC–MS/MS and Its Application in Pharmacokinetics Study

Identification of Impurities in Methotrexate Drug Substances Using High-Performance Liquid Chromatography Coupled with A Photodiode Array Detector and Fourier Transform Ion Cyclotron Resonance Mass Spectrometry

Impurity Identification and Scale-Up of a Novel Glycopeptide Antibiotic

Detection of Two Genotoxic Impurities in Drug Substance and Preparation of Imatinib Mesylate by LC–MS/MS

Identification, trace level quantification, and in silico assessment of potential genotoxic impurity in Famotidine

Comprehensive analysis of vitamin D3 impurities in oily drug products using supercritical fluid chromatography–mass spectrometry

Identification, Separation and Characterization of Process-Related Impurities of Bifendate Derivative (DB-6), an Investigational Agent Combating Acute Liver Failure.

Development, stability-indicating assessment, and evaluation of influential method conditions using a full factorial design for the determination of Nintedanib esylate-related impurities

Characterization of Elvitegravir and Its Related Impurities Using ESI–LC–MS, NMR Techniques, Method Development and Validation of Its Related Substances by HPLC Method

Development and validation for bioanalysis of VK2809, its active metabolite VK2809A and glutathione-conjugated metabolite MB06588 in rat liver using LC-MS/MS

Identification, Characterization, Synthesis and Quantification of Related Impurities of Liguzinediol.

Novel IMB16-4 Compound Loaded into Silica Nanoparticles Exhibits Enhanced Oral Bioavailability and Increased Anti-Liver Fibrosis In Vitro

An innovative impurity profiling of esmolol hydrochloride injection using UPLC-MS based multiple mass defect filter, chemometrics and in-silico toxicity prediction

Stability-indicating HPTLC method for the simultaneous detection and quantification of alfuzosin hydrochloride, solifenacin succinate along with four of their official impurities

A Liquid Chromatography-mass Spectrometry Method to Determine the Content of Genotoxic Impurity Piperidine in Rimonabant

Separation, Determination of Six Impurities in Methotrexate Drug Substance Using Ultra-Performance Liquid Chromatography

Identification and Analysis of an Impurity Inducing Clinical Adverse Effect in Anti-Adhesion Carboxymethyl Chitosan Products.